News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
百濟神州(06160.HK)安泰適在內地獲批用於小細胞肺癌二線治療
百濟神州(06160.HK)宣布，由公司與安進(Amgen)共同負責在中國大陸開發和商業化的首個且目前唯一獲批的靶向DLL3和CD3的雙特異性T細胞銜接器(TCE)抗體安泰適(注射用塔拉妥單抗)獲得國家藥品監督管理局(NMPA)批准，用於既往接受過1種系統性治療(包括含鉑化療)失敗的廣泛期小細胞肺癌(ES-SCLC)成人患者，即二線治療。(su/da)~阿思...
Reset
Send
The window will close in 5 seconds
百濟神州(06160.HK)安泰適在內地獲批用於小細胞肺癌二線治療
Close
Recommend
1
Positive
4
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

百濟神州(06160.HK)  +0.100 (+0.061%)    Short selling $417.64M; Ratio 20.614%   宣布，由公司與安進(Amgen)共同負責在中國大陸開發和商業化的首個且目前唯一獲批的靶向DLL3和CD3的雙特異性T細胞銜接器(TCE)抗體安泰適(注射用塔拉妥單抗)獲得國家藥品監督管理局(NMPA)批准，用於既往接受過1種系統性治療(包括含鉑化療)失敗的廣泛期小細胞肺癌(ES-SCLC)成人患者，即二線治療。(su/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-08 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.